CLAUSEN PETER 4

What Happened

• Peter Clausen, CSO and COO of Nuo Therapeutics (AURX), received a grant of 65,000 derivative securities (reported as an award) on June 29, 2026. The Form 4 reports an acquisition price of $0.00 and shows a reported value of $0 for the grant; a footnote identifies these as options with a vesting schedule.

Key Details

• Transaction date: 2026-06-29; filing date: 2026-07-02 (no late-file flag in the filing).
• Security/amount: 65,000 derivative securities (stock options) reported at $0.00 per share; total reported value $0.
• Vesting: Footnote — one-third of the options are exercisable as of June 30, 2027; the balance vests quarterly over the subsequent two years.
• Shares owned after transaction: not disclosed in this Form 4.
• Transaction type code: A (award/grant); no sale or open-market purchase occurred.

Context

• This is an option award to an executive, not an immediate purchase or sale. The award does not involve cash paid at grant; exercising the options in the future would typically require meeting vesting conditions and paying any exercise price (not specified in the filing). Grants are common for executive compensation and do not by themselves indicate a buy/sell signal.